<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696342</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH157-0217/III</org_study_id>
    <nct_id>NCT03696342</nct_id>
  </id_info>
  <brief_title>Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.</brief_title>
  <acronym>PRO-157</acronym>
  <official_title>Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative&#xD;
      group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the&#xD;
      treatment of bacterial conjunctivitis.&#xD;
&#xD;
      Goal:To compare the efficacy of the ophthalmic solution of pazufloxacin 0.6%, against the&#xD;
      ophthalmic solution of gatifloxacin 0.3%, in the treatment of acute bacterial conjunctivitis.&#xD;
&#xD;
      Hypothesis:the ophthalmic solution PRO-157 is not inferior in the treatment of bacterial&#xD;
      conjunctivitis, compared to the ophthalmic solution of gatifloxacin 0.3%, by means of the&#xD;
      clinical remission of the disease.&#xD;
&#xD;
      Number of patients:&#xD;
&#xD;
      160 patients, each one will provide an eye for efficacy analysis, divided into 2 groups (80&#xD;
      eyes per group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study subjects will be recruited from various research centers in western and central&#xD;
      Mexico.&#xD;
&#xD;
      Each research center has a monitoring plan specified according to the recruitment&#xD;
      capabilities of the same, which must be at least once a month, where the queries of your data&#xD;
      entered into the electronic case report report will be reported to the center. (e-CRF) for&#xD;
      which it has as time limit the next monitoring visit to make the pertinent changes.&#xD;
&#xD;
      The report of adverse events will be made according to the standard operating procedure (PNO)&#xD;
      where it specifies, according to Official Mexican Standard 220 (NOM 220), that the signs or&#xD;
      symptoms of adverse events will be reported based on the Medical Dictionary. for Regulatory&#xD;
      Activities, for which the sponsor has version 20.1 in Spanish. For serious adverse events&#xD;
      (SAEs) will be reported in accordance with the standardized operation procedure of&#xD;
      pharmacovigilance of the sponsor, which adheres to the guidelines of NOM 220 and&#xD;
      international regulations, these will be reported in the regulatory framework to the&#xD;
      regulatory entity within a period of time no more than 7 days.&#xD;
&#xD;
      The study is registered in the National Registry of Clinical Trials (RNEC), entity equivalent&#xD;
      to Clinical Trials in Mexico.&#xD;
&#xD;
      The quality assurance plan is carried out by the sponsor through the Quality Assurance agent&#xD;
      in Clinical Research, whose function is to conduct inspections and audits of the research&#xD;
      sites to document and generate reports of deviations from the protocol. In addition to the&#xD;
      visits of the monitoring plan, the reliability of the data is guaranteed.&#xD;
&#xD;
      To verify the integrity, veracity and reliability of the data entered into the e-CRF, the&#xD;
      monitors of each center will check the information uploaded to the portal with that reported&#xD;
      in the source document of the principal investigator (PI), such as clinical notes, clinical&#xD;
      history and documents. and formats attached to the research protocol, physical case report&#xD;
      format, as well as those provided by the sponsor to the PI (subject's diary and quality and&#xD;
      satisfaction survey).&#xD;
&#xD;
      The e-CRF used for this clinical study is provided by an internationally certified provider&#xD;
      with the highest quality standards, protection of information under current regulations and&#xD;
      confidentiality guarantee. The information that the PIs enter into the e-CRF is collated and&#xD;
      verified by the clinical monitors and by the service provider's personnel, later reviewed and&#xD;
      approved by the medical ophthalmologist researcher and by the Clinical Security&#xD;
      Pharmacologist, who authorize the monitored data of clinical information and safety of the&#xD;
      study molecule, respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's convenience&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>clinical study of non-inferiority, multicenter, double-blind, with comparative group randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>In addition, the statistical analysis will be carried out in a blinded manner in the case of a partial and final analysis.&#xD;
The masking will be done using boxes in the primary packaging identical in the two groups and relabelling the bottles of both interventions.&#xD;
Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the assignment number.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Conjunctival Secretion Present in Each Patient by the End of Treatment</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The ocular secretion will be classified as 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The number will be reported according to the rating granted at final visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severeness of Conjunctival Bulbar Hyperemia in Each Patient by the End of Treatment</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. Will be graduated using the Efron scale.&#xD;
0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Rating (Global Qualification) of Product's Efficacy as Classified by Main Investigator by the End of Treatment</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The global qualification of the investigator constitutes the integral judgment of the clinical picture of the subject, including signs and symptoms, after a routine ophthalmological evaluation and interrogation. It will be classified 0 = cure, 1 = improvement, 2 = no changes compared to before starting treatment, 3 = worsened. It will be registered in the CRF in each of the follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Bacterial Eradication Compared to Baseline Culture Results</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The conjunctival secretion sample will be taken prior to the instillation of any medication, the result of the basal crop will be compared against the results of the final crop and the absence of bacterial species that were present in the culture of the baseline visit is considered bacterial eradication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>day 0 to day 17 (visit 0 to security call)</time_frame>
    <description>The evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection. the number of adverse events per study group will be considered for the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Clinical Remission Defined as Absence of Hyperemia and Secretion by the Final Visit</measure>
    <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
    <description>The clinical remission in the visits will be evaluated as &quot;Yes&quot; or &quot;No&quot;, to report &quot;Yes&quot; it must have a grade of &quot;0&quot; in conjunctival hyperemia and &quot;0&quot; in secretion; otherwise, you must report as &quot;No&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Conjunctivitis, Bacterial</condition>
  <arm_group>
    <arm_group_label>PRO-157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zymar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazufloxacin</intervention_name>
    <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
    <arm_group_label>PRO-157</arm_group_label>
    <other_name>PRO-157</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zymar</intervention_name>
    <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
    <arm_group_label>Zymar</arm_group_label>
    <other_name>gatifloxacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Age ≥ 1 year.&#xD;
&#xD;
          -  Both genders.&#xD;
&#xD;
          -  Clinical picture of acute bacterial conjunctivitis defined by: Conjunctival secretion&#xD;
             and conjunctival bulbar hyperemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, lactating or planning to become pregnant.&#xD;
&#xD;
          -  Women of reproductive age and who do not have a hormonal contraceptive method,&#xD;
             intrauterine device or bilateral tubal obstruction.&#xD;
&#xD;
          -  Participation in another clinical research study ≤ 30 days before the baseline visit.&#xD;
&#xD;
          -  Previous participation in this same study.&#xD;
&#xD;
          -  That they can not comply with their attendance at appointments or with all the&#xD;
             requirements of the protocol.&#xD;
&#xD;
          -  Single eye&#xD;
&#xD;
          -  Presence of corneal abrasion or corneal ulceration in the study eye.&#xD;
&#xD;
          -  History Users of contact lenses who are not willing to suspend their use during the&#xD;
             study.&#xD;
&#xD;
          -  Users of any formulation with ophthalmic application, including lubricants, that can&#xD;
             not, or do not want to suspend it during the study.&#xD;
&#xD;
          -  Antecedents of eye surgery 6 weeks prior to study entry.&#xD;
&#xD;
          -  Viral or allergic conjunctivitis.&#xD;
&#xD;
          -  Active uveitis.&#xD;
&#xD;
          -  Active ulcerative keratitis.&#xD;
&#xD;
          -  Recurrent corneal erosion syndrome&#xD;
&#xD;
          -  Antecedent of hypersensitivity or allergy to fluoroquinolones.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consultorio Dra. Patricia Culebro Solano</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juan Carlos Ochoa Tavares</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel altamirano Vallejo</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de investigación Medica Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20116</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juan Carlos Serna Ojeda (INBIOMEDyC)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pazufloxacin</keyword>
  <keyword>PRO-157</keyword>
  <keyword>Fluoroquinolones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>Pazufloxacin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03696342/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRO-157</title>
          <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Zymar</title>
          <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PRO-157</title>
          <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Zymar</title>
          <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.78" spread="22.8"/>
                    <measurement group_id="B2" value="49.65" spread="29.2"/>
                    <measurement group_id="B3" value="48.22" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive culture</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severe conjunctival secretion</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severe bulbar conjunctival hyperemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="23"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Conjunctival Secretion Present in Each Patient by the End of Treatment</title>
        <description>The ocular secretion will be classified as 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The number will be reported according to the rating granted at final visit.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Conjunctival Secretion Present in Each Patient by the End of Treatment</title>
          <description>The ocular secretion will be classified as 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The number will be reported according to the rating granted at final visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severeness of Conjunctival Bulbar Hyperemia in Each Patient by the End of Treatment</title>
        <description>Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. Will be graduated using the Efron scale.&#xD;
0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Severeness of Conjunctival Bulbar Hyperemia in Each Patient by the End of Treatment</title>
          <description>Conjunctival hyperemia is defined as the simplest reaction of the conjunctiva to a stimulus, a red appearance secondary to the vasodilation of the conjunctival vessels of variable intensity. Will be graduated using the Efron scale.&#xD;
0 Normal , 1 Very slight, 2 Mild, 3 Moderate, 4 Severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating (Global Qualification) of Product's Efficacy as Classified by Main Investigator by the End of Treatment</title>
        <description>The global qualification of the investigator constitutes the integral judgment of the clinical picture of the subject, including signs and symptoms, after a routine ophthalmological evaluation and interrogation. It will be classified 0 = cure, 1 = improvement, 2 = no changes compared to before starting treatment, 3 = worsened. It will be registered in the CRF in each of the follow-up visits.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating (Global Qualification) of Product's Efficacy as Classified by Main Investigator by the End of Treatment</title>
          <description>The global qualification of the investigator constitutes the integral judgment of the clinical picture of the subject, including signs and symptoms, after a routine ophthalmological evaluation and interrogation. It will be classified 0 = cure, 1 = improvement, 2 = no changes compared to before starting treatment, 3 = worsened. It will be registered in the CRF in each of the follow-up visits.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Bacterial Eradication Compared to Baseline Culture Results</title>
        <description>The conjunctival secretion sample will be taken prior to the instillation of any medication, the result of the basal crop will be compared against the results of the final crop and the absence of bacterial species that were present in the culture of the baseline visit is considered bacterial eradication.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Bacterial Eradication Compared to Baseline Culture Results</title>
          <description>The conjunctival secretion sample will be taken prior to the instillation of any medication, the result of the basal crop will be compared against the results of the final crop and the absence of bacterial species that were present in the culture of the baseline visit is considered bacterial eradication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>The evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection. the number of adverse events per study group will be considered for the analysis</description>
        <time_frame>day 0 to day 17 (visit 0 to security call)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The evaluation of adverse events requires a questioning conducted by the principal investigator and the appropriate exploratory techniques for its detection. the number of adverse events per study group will be considered for the analysis</description>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presence of Clinical Remission Defined as Absence of Hyperemia and Secretion by the Final Visit</title>
        <description>The clinical remission in the visits will be evaluated as &quot;Yes&quot; or &quot;No&quot;, to report &quot;Yes&quot; it must have a grade of &quot;0&quot; in conjunctival hyperemia and &quot;0&quot; in secretion; otherwise, you must report as &quot;No&quot;.</description>
        <time_frame>will be evaluated at the end of the treatment (day 8, final visit)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-157</title>
            <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Zymar</title>
            <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Presence of Clinical Remission Defined as Absence of Hyperemia and Secretion by the Final Visit</title>
          <description>The clinical remission in the visits will be evaluated as &quot;Yes&quot; or &quot;No&quot;, to report &quot;Yes&quot; it must have a grade of &quot;0&quot; in conjunctival hyperemia and &quot;0&quot; in secretion; otherwise, you must report as &quot;No&quot;.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 1 (basal visit) to the safety call on day 15 (±2 days)</time_frame>
      <desc>The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>PRO-157</title>
          <description>Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Pazufloxacin: Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Zymar</title>
          <description>Gatifloxacin 0.3%. by Allergan, topical ophthalmic 1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.&#xD;
Zymar: Gatifloxacin 0.3%. by Allergan, topical ophthalmic&#xD;
1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Preexcitation syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="23"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ocular Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Blepharoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Palpebral hyperemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ocular irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Transparent Filament Presence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ocular dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sprain</sub_title>
                <description>Grade 1</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was terminated early due to the sponsor's convenience in the pipeline followed by the studied product. A small sample renders this results as merely descriptive.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Alejandra Sanchez-Rios</name_or_title>
      <organization>Medical Affairs Operations Chief</organization>
      <phone>33 3001 4200 ext 1190</phone>
      <email>alejandra.sanchez@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

